Search
Home
News
Fortune 500
Fortune Global 500
Fortune 500 Europe
Fortune China 500
Fortune SEA 500
Great Place To Work
Tech
AI
Innovation
Cybersecurity
Finance
Personal Finance
Real Estate
Economy
Investing
Banking
Crypto
Leadership
Success
Future Of Work
Workplace Culture
C-Suite
CEO Initiative
Lifestyle
Arts & Entertainment
Travel & Leisure
Health
Well
Education
Rankings
Analytics
Multimedia
Live Media
Magazine
Newsletters
Video
Podcasts
Home
News
Fortune 500
Fortune 500
Fortune Global 500
Fortune 500 Europe
Fortune China 500
Fortune SEA 500
Great Place To Work
Tech
Tech
AI
Innovation
Cybersecurity
Finance
Finance
Personal Finance
Real Estate
Economy
Investing
Banking
Crypto
Leadership
Leadership
Success
Future Of Work
Workplace Culture
C-Suite
CEO Initiative
Lifestyle
Lifestyle
Arts & Entertainment
Travel & Leisure
Health
Well
Education
Rankings
Rankings
Analytics
Multimedia
Multimedia
Live Media
Magazine
Newsletters
Video
Podcasts
Asia
Europe
Analytics
home
home
obesity
obesity
Page 5 of 12
Lifestyle
Novo Nordisk faces competition close to home as Danish rival Zealand Pharma’s shares jump 35% on ‘groundbreaking’ weight-loss drug trial results
By
Prarthana Prakash
February 27, 2024
Retail
Novo Nordisk’s CEO says he’s fielding calls from ‘scared’ junk food suppliers asking for advice over Ozempic surge
By
Ryan Hogg
February 8, 2024
Health
Experimental once-a-month weight loss injectable shows lasting results in early study
By
Madison Muller
and
Bloomberg
February 5, 2024
Health
WeightWatchers’ worst month ever—a stark reversal of 2023—wipes out obesity-drug gains
By
Katrina Compoli
and
Bloomberg
February 2, 2024
Health
Weight-loss injectables like Zepbound are making as big of a splash as Viagra, if not bigger. What you need to know about the ‘miracle drugs’
By
Emma Court
,
Madison Muller
and
Bloomberg
January 31, 2024
Retail
Novo Nordisk hits $500B market value, climbing closer to the $1T club as it forecasts Wegovy and Ozempic will juice another 29% jump in profits this year
By
Ryan Hogg
January 31, 2024
Health
North Carolina drops coverage for Wegovy and Ozempic, with implications for anti-obesity drug market projected to hit $100B by 2030
By
Simone Foxman
,
Madison Muller
and
Bloomberg
January 27, 2024
Health
Millions of older Americans can’t get weight loss drugs like Wegovy because Medicare won’t pay for them
By
Amanda Seitz
and
The Associated Press
December 28, 2023
Health
Nearly half of the U.S. population has diabetes or prediabetes—and many have no clue. Are you among them?
By
Erin Prater
December 23, 2023
Health
Severe obesity increasing among young American children, new study confirms
By
Mike Stobbe
and
The Associated Press
December 18, 2023
Finance
Roche pushes to catch up to Novo Nordisk’s Wegovy with $3.1bn deal for obesity drugmaker Carmot
By
Paula Doenecke
and
Bloomberg
December 4, 2023
Health
Novo Nordisk responds to U.S. rival Eli Lilly by announcing new $2.3 billion investment in France to keep up with soaring demand for weight-loss drugs
By
Reuters
November 23, 2023
Health
Obesity drugs in Ozempic, Wegovy and Mounjaro are trimming back the Thanksgiving ‘food orgy’
By
Jonel Aleccia
and
The Associated Press
November 20, 2023
Retail
So many Americans are using Novo Nordisk’s blockbuster weight loss-aiding Ozempic that Germany may ban exports of the drug
By
Ryan Hogg
November 16, 2023
Health
A ‘game-changing’ study backs Wegovy use to cut heart attacks and strokes: ‘This is not just about weight and appearance’
By
Madison Muller
,
Naomi Kresge
and
Bloomberg
November 11, 2023
Most Popular
C-Suite
'I’ve spent my entire life making YouTube videos. They’ve spent their entire lives helping people': MrBeast teams with...
By
James Pollard
and
The Associated Press
Success
Half of workers are 'revenge quitting' and walking out on their jobs without notice—and the majority are loyal,...
By
Orianna Rosa Royle
AI
'I'm not going back': Billionaire Marc Benioff says he's switching to Google's Gemini 3 after using 'ChatGPT every day...
By
Dave Smith